Ketorolac is a potent nonsteroidal antiinflammatory drug (NSAID). In adult humans and animals, its analgesic efficacy can be comparable to opiates. However, it has not been studied in neonatal animals. We conducted a blinded, controlled study comparing the effects of ketorolac and morphine in neonatal rats using the formalin model. Animals were given intraperitoneal (ip) injections of ketorolac or morphine at 3 or 21 days of age. Ketorolac had an analgesic and antiinflammatory effect in 21-day-old pups, but not in the 3-day-olds. Morphine had a significant analgesic, but no antiinflammatory effect at both ages. These results indicate that ketorolac is an effective analgesic agent in preweaning, but not neonatal rats. Opiates may be more appropriate analgesics in neonates. D 2001 Elsevier Science Inc. All rights reserved.
Background
Ketorolac is one of the most potent nonsteroidal antiinflammatory (NSAID) drugs available for clinical use. It can be administered orally, parenterally, and topically (for ocular inflammation). Its effects are mainly peripheral due to nonselective inhibition of cyclo-oxygenase and subsequent reduction of prostaglandin production (especially prostaglandin E2) (Zhang et al., 1997) . Data from animal studies also suggest that ketorolac may have a central modulatory effect on opioid pharmacology (Maves et al., 1994) .
In human adults, ketorolac has been extensively evaluated in the relief of postoperative pain and other acute pain states. It has similar analgesic efficacy as morphine and meperidine in relieving postoperative pain, and is tolerated well with few side effects (renal, gastrointestinal, platelet function) (Gillis and Brogden, 1997) . In the emergency department, in patients with renal colic (Larkin et al., 1999) , migraine headache, musculoskeletal pain, or sickle crisis, ketorolac reduces pain as effectively as opiates (Gillis and Brogden, 1997) . Ketorolac also has a synergistic effect with morphine and fentanyl and reduces the need for opiates in the postoperative period in both human adults (Picard et al., 1997) and children (Chiaretti et al., 1997) . The combination of ketorolac and opiates allows the use of subtherapeutic doses of both drugs and reduction in their side effects. In the pediatric population, ketorolac has mostly been used in children over the age of 2 years. Its analgesic efficacy is comparable to opiates in strabismus surgery (Shende and Das, 1999) , bladder surgery (Gonzalez and Smith, 1998) , tonsillectomy (Mather and Peutrell, 1995) , and dental surgery (Purday et al., 1996) . There is no reported experience with its use in human neonates.
When tested in animal models, ketorolac is an effective analgesic, antiinflammatory and antipyretic drug in adult rats (Rooks, 1990; Jett et al., 1999) and mice (Uphouse et al., 1993) . In rats, its analgesic efficacy is 300 ± 500 times that of aspirin (Rooks et al., 1985) . In adult rat models of inflammatory pain using intraarticular injection of uric acid, ketorolac is as effective as morphine and more potent than aspirin in relieving pain. (Granados-Soto et al., 1993) . For adult animals, the range of effective doses and types of inflammatory models reported in literature is wide, from 1 mg/kg in rats with uric-acid-induced arthritis (GranadosSoto et al., 1993) up to 200 mg/kg in rats injected with formalin (Bustamente and Paeile, 1993) . In the rat formalin test, two phases of nociceptive behavior are seen following formalin injection into the subcutaneous space, phase 1 (0 ± 10 min) is pain produced by direct stimulation and phase 2 (10 min ± 1 h) is pain due to sensitization of primary afferents and the spinal cord. In adult rats, ketorolac reduced phase 2 of inflammation-induced pain, but had no effect on phase 1 pain. There are no data on the analgesic efficacy of ketorolac in animal neonatal models. Therefore, we studied its analgesic and antiinflammatory effects in neonatal and infant rats using the formalin model to produce acute pain and inflammation. A behavioral scoring system was used to assess pain, paw diameter was measured to assess inflammation, and Fos staining of spinal cord sections was used to assess neural response to pain. Our hypothesis was that ketorolac would be an effective analgesic and antiinflammatory agent in neonatal and preweaning rats, with analgesic efficacy comparable to that of morphine.
Materials and methods
This was a randomized, blinded, controlled study using a total of 136 rat pups. All experiments were approved by New York State Psychiatric Institute IACUCs and followed Ethical Guidelines of the Society for Neuroscience and the International Society for Developmental Psychobiology.
Experimental animals
Subjects were awake Long± Evans hooded rat pups (3 and 21 days old). They were born and bred in our animal facility. The pups were housed with their mothers in plastic cages measuring 40 Â 20 Â 24 cm with bedding, food and water available ad libitum. The cages were in a colony room maintained at 24°C with a 12-h light ±dark cycle (lights on at 08:00 hours). Cages were checked twice a day at 09:00 and 18:00 hours and pups found at either time were designated 0 days of age. Pups were separated from their mothers immediately prior to the experiment and were kept warm using incubators/heating pads.
Drug preparation and administration
The drugs used in this study were ketorolac (15 ±45 mg/kg ip; Toradol, Roche, Nutley, NJ) and morphine sulfate (0.1 ± 2 mg/kg ip; Merck, Rahway, NJ). Drugs were dissolved in 0.9% saline solution and injected in volumes of 1 cc/100 g body weight 1 h prior to the formalin injection for ketorolac and half an hour prior to formalin injection for morphine. Three-day-old rats were given intraperitoneal (ip) injections of either saline or ketorolac 15, 35, and 45 mg/kg, or morphine 0.1, 0.3, and 1.0 mg/kg. Older rats were given intraperitoneal injections of either saline or ketorolac 15, 35, and 45 mg/kg, or morphine 0.2, 0.6, and 2.0 mg/kg. All doses were given within litter. Lower doses were used in the younger animals, since morphine is more potent in younger animals.
Formalin
Ten microliters of 2% formalin was injected into the subcutaneous space of the plantar aspect of the left hindpaw. Pain behavior was recorded for a period of 60 min, starting immediately after the formalin injection. The pain behavior was recorded at 1-min intervals, using a four-point scale as described below:
Score 1 Ð paw resting on surface (similar to uninjected paw). Score 2 Ð paw lifted up above the surface. Score 3 Ð paw shaken. Score 4 Ð paw licked. Fig. 1 . Mean ( S.E.M.) nociceptive scores across the first 15 three-minute bins in 3-and 21-day-old rat pups that received intraperitoneal saline, 15, 35, or 45 mg/kg of ketorolac prior to an intraplantar injection of 2% formalin (10 ml). The older animals treated with ketorolac showed a reduction in nociceptive scores during phases 1 and 2 and a dose ± response effect was seen ( P < .01 with 45 mg/kg ketorolac). No significant effect was seen in younger pups.
Paw diameter
One hour after the formalin injection, the dorso-ventral diameter of right and left hindpaw of each pup was measured using calipers accurate to 0.001 in.. The right hindpaw diameter served as a control for the degree of inflammation in the left hindpaw. Data are expressed as diameter of control paw divided by diameter of inflamed paw multiplied by 100.
Immunocytochemistry
We performed quantitative immunocytochemistry of spinal cords for Fos staining. There is evidence of some correlation between Fos staining and behavioral nociception in infant animals (Yi and Barr, 1995) . A reduction in Fos staining of the spinal cord has also been reported with analgesia induced by opioids (Gogas et al., 1996) and NSAIDs (Buritova et al., 1995) . Since the expression of Fos protein in the dorsal horn of the spinal cord peaks at 2 h after formalin injection, pups were sacrificed at this time and perfused with phosphate buffered saline followed by paraformaldehyde as previously described (Yi and Barr, 1995) . Thirty-micron sections of the lumbar enlargement of the spinal cord were stained for Fos protein using the avidin± biotin ± peroxidase method. Fos-stained nuclei were counted as described previously (Yi and Barr, 1995) . Each section was subdivided into five regions, and all stained nuclei within each region were counted. For each pup, nuclei were counted from five sections, and the mean number of stained nuclei per region was obtained. We did not measure Fos in the morphine group, since previous studies have shown reduction in Fos staining with morphine at both 3 and 21 days of age (Yi and Barr, 1998) . We realize that behavioral testing and Fos staining are not isomorphic measures of nociception. However, since the 3-day pups treated with ketorolac did not show any difference in their behavioral scoring, we decided not to examine their spinal cords for Fos staining. Thus, we used Fos expression as a confirmation of the behavioral results in the 21-day-old pups treated with ketorolac, and to identify a reduction of nociceptioninduced Fos expression at the level of the spinal cord.
Statistics
For the behavioral analysis, the minute-by-minute data were averaged into 3-min bins to decrease the variability. The pain score for each 3-min bin (during the first 45 min) was analyzed using two-way analysis of variance (ANOVA) with the 3-min bins (n = 15) and drug dose as within-subjects variables. Although pain scores were recorded over 60 min, only the first 45 min were analyzed since the 21-day-old pups showed no nociceptive behavior in the last 15 min of Fig. 2 . Mean ( 1 S.E.M.) nociceptive scores across the first 15 threeminute bins in 3-day-old rat pups that received intraperitoneal saline, 0.1, or 0.3 mg/kg of morphine and 21-day-old rat pups that received intraperitoneal saline, 0.2, 0.6, or 2.0 mg/kg of morphine prior to an intraplantar injection of 2% formalin (10 ml). The highest dose in 3-day-old pups was sedating. In both groups, morphine reduced nociceptive scores during phases 1 and 2. In 3-day-old pups, both low and medium doses showed a significant effect ( P < .01), and in 21-day-old pups, medium dose ( P < .05) and high dose ( P < .01) showed a significant effect. the 60-min observation period. For the inflammation assessment, an ANOVA was performed, with the paw diameter and the drug dose as within-subjects variables. For the Fos analysis, a one-way ANOVA was used, with the drug dose as the within-subjects variable. Post hoc analysis was performed for drug-dose effects using the Newman ± Keuls test. Statistical tests were considered significant if P .05.
Results

Behavioral assessment: pain scores
Ketorolac
At 3 days of age, there was no reduction in pain scores at any dose of ketorolac (Fig. 1) . As expected at this age, the scores remained high throughout, with no clear distinction of phases 1 and 2 (Barr, 1998; Guy and Abbott, 1992; Teng and Abbott, 1998) (Fig. 3) . At 21 days of age, a dosedependent reduction in pain scores was seen ( F 3,21 = 6.11, P < .01). On post hoc analysis, a statistically significant difference was seen between saline-treated animals and those treated with 45 mg/kg (highest dose) ketorolac ( P < .01) (Fig. 2) . There was no significant interaction between dose and bins, i.e. the dose effect was consistent through all of the bins ( F 42,294 = 0.67, P > .05).
Morphine
The 3-day-old pups treated with the highest dose of morphine appeared sedated, and we tested a separate group of pups of the same age for the righting reflex, with morphine [0.1, 0.3, or 1 mg/kg to 3-day-old pups (n = 3/dose)]. At the highest dose, the righting reflex was abolished; at the low and medium doses, the righting reflex was preserved and the animals did not appear sedated. Thus, we did not include the high dose data in the analysis. The 3-day-old pups demonstrated a statistically significant, dose-dependent reduction in pain scores ( F 2,14 = 24.3, P < .01) (Fig. 2) . There was no significant interaction between dose and bins ( F 28,196 = 1.03, P > .05). Post hoc analysis showed that both doses ( P < .01) significantly reduced pain scores relative to the saline vehicle. At 21 days of age, there was a statistically significant reduction in pain scores ( F 3,27 = 8.04, P < .01), with no significant interaction between dose and bins ( F 42,378 = 1.02, P > .05) (Fig. 3) . On post hoc analysis, the medium (0.6 mg/ kg) ( P < .01) and high (2 mg/kg) ( P < .05) doses of morphine showed a significant reduction in nociceptive responding relative to the vehicle control. There was no difference between the medium and high doses ( P >.05).
Inflammation: paw diameter
All animals had edema in their formalin-injected paws, and the injected hindpaw diameters were greater than the control hindpaw diameters. At 3 days, there was no reduction in left hindpaw diameters in the ketorolac treated animals compared to controls. At 21 days, animals treated with the highest dose ketorolac had significantly less edema in the left paw, as measured by paw diameter, compared to control animals ( P < .05) (Fig. 3) . There was no reduction in the diameter of the formalin injected paw in the morphinetreated animals (data not shown).
Neural response: Fos
In the 21-day animals treated with ketorolac, we compared the Fos staining in the spinal cord on the side of the formalin injection between the saline treated group and the high-dose ketorolac group. Since the Fos staining was largely absent in the dorsal horn of the contralateral side, we did not analyze that side. We found a trend towards reduced staining in the ketorolac treated animals ( P= .055) (Figs. 4 and 5) . The most prominent difference as expected was seen in area A, which corresponds with the medial aspects of Laminae 1 and 2 (Fig. 5 ).
Discussion
Ketorolac is an effective analgesic and antiinflammatory drug in the formalin model in adult rats with a range of minimal effective doses between 4.5 and 40 mg/kg (Randolph and Peters, 1997; Bustamente and Paeile., 1993) . In our study, in 21-day-old rats injected with subcutaneous formalin, ketorolac was also effective as an analgesic agent, as seen by the reduction in pain scores on behavioral testing, and as an antiinflammatory agent, as seen by the reduction in paw edema. At this age, ketorolac caused a reduction in pain scores through all the bins, i.e. through phases 1 and 2. In adult rats, ketorolac had an effect only during phase 2 of the formalin test (Randolph and Peters, 1997) . Ketorolac-treated rats also showed a trend towards reduced Fos staining in their spinal cords, which is consistent with the behavioral data showing that ketorolac attenuates nociception at this age. The maximal response for analgesia was seen at 45 mg/kg. In adult rats, ketorolac had an analgesic effect at 40 mg/kg, but not at 20 mg/kg (Bustamente and Paeile., 1993) . Thus, the doses that we found effective at 21 days of age were closer to those in the study by Bustamente and Paeile Ketorolac, at the age of 3 days, did not show any significant analgesic or antiinflammatory activity. At this age, we did not see a biphasic response in the pain scores, this is consistent with previous reports (Barr, 1998; Guy and Abbott, 1992; Teng and Abbott, 1998) . Whether higher doses of ketorolac would be effective at this age is not known. The role of prostaglandins in inflammatory hyperalgesia in neonatal rats is also not known. Since there is no definite second phase, it is possible that they do not play a major role, and this may be the reason why we did not see a response to ketorolac at this age. Other mediators such as glutamate may play a more significant role in inflammation at the younger ages. Another explanation for ketorolac's inefficacy may be because of different pharmacokinetics of ketorolac in neonatal rats, but we are not aware of any such data.
Morphine produced significant reduction in pain scores in 3-and 21-day-old rats. There was no effect on inflammation as treatment with morphine did not reduce paw edema. This was not unexpected, since morphine has no antiinflammatory activity. We recognize that it is difficult to compare the two ages because of the different doses used, but morphine is known to be more potent in younger rat pups, part of the reason being their immature blood ±brain barrier. At 0.1 and 0.3 mg/kg, there was significant reduction in pain scores without apparent sedation across the 45-min session. The control animals in the 3-day morphine group had higher scores than the control group in the 3-day ketorolac animals, and we cannot explain this difference other than interlitter variations. Although the scores of the morphine-treated animals are similar to the scores of the control animals in the ketorolac group, we think that the effect of morphine is real, since each experiment compared drug doses between littermates, thus, minimizing interlitter variations. In 21-day-old rats, both the medium and high doses produced a statistically significant reduction in pain scores in both phases of the test. In adult rats also, morphine has been shown to reduce pain scores in both phases of the test (Randolph and Peters, 1997) .
On the basis of brain growth rate, neonatal rats are equivalent to human preterm infants of 26 weeks gestational age, 7-day-old rat pups are equivalent to term human neonates and 21-day-old rats are equivalent to young children (Dobbing, 1981) . This study demonstrates that ketorolac is an active analgesic and antiinflammatory drug in 21-day-old rats, but not in 3-day-old rats; whether it is effective at intermediate ages remains to be seen. We also confirmed that morphine is a potent analgesic agent in 3-and 21-day-old rats. Though the analgesic effects of both ketorolac and morphine were modest in 21-day-old pups, morphine is clinically a potent analgesic in human neonates. This study may have some clinical relevance in that ketorolac may not be effective in human premature infants, but may be effective at an older age, i.e. term or during infancy, and morphine or other opiates may be the analgesic drugs of choice in premature babies.
